Acelity’s innovative negative-pressure wound therapy system changes the game by enhancing delivery of four therapies on a single device
SANTA CLARA, Calif. — September 15, 2017 — Based on its recent analysis of the negative-pressure wound therapy (NPWT) market, Frost & Sullivan recognizes Acelity with the 2017 North American Negative-Pressure Wound Therapy Product Leadership Award for its new two new therapies: V.A.C.ULTA™ 4 Therapy System, which incorporates a fifth-generation software upgrade that provides delivery of four therapies on a single device, allowing physicians to treat various wounds with a single system, and V.A.C. VERAFLO CLEANSE CHOICE™ Dressing, which provides clinicians with a novel, adjunctive non-surgical option that may help clean large complex wounds when complete surgical debridement is not possible or appropriate.
Healthcare economies, such as the United States (US), are faced with shifting challenges, including rising operational costs at hospitals, staffing constraints, and cost burdens carried by care facilities for hospital-acquired infections. While US healthcare policies, along with value-based reimbursement models, are a clinical and economic driver in the wound care market, the need exists for wound care companies to integrate their treatment modalities into new care models that better track and manage chronic wounds across various care settings due to the shift from pay-for-service models to pay-for-performance and quality-of-care based payment models. The current chronic wound care market is also significantly fragmented because of the many ways a typical wound can be treated, including active healing dressings, advanced passive dressings, other unique energy- or mechanical-based solutions, and negative-pressure wound treatment systems (NPWT), including vacuum assisted-closure (V.A.C.®) therapy.
“Acelity is a leading provider of advanced wound care solutions,” said Patrick Riley, Principal Analyst at Frost & Sullivan. “The company pioneered NPWT, and its advanced V.A.C. VERAFLO™ Therapy combines the benefits of V.A.C.® Therapy and automated topical wound solution distribution and removal to help heal and prepare the wound for closure quickly and effectively. The new V.A.C.ULTA™ 4 Therapy System sets the benchmark with its capability to delivery four therapies through a single device.”
The four therapies include:
- V.A.C. VERAFLO™ Therapy with Instillation, which automates alternating cycles of wound cleansing with a topical solution and V.A.C.® Therapy, allowing for wound cleansing and therapy to maintain a closed environment to enhance healing. V.A.C. VERAFLO™ Therapy is poised to become the new gold standard of NPWT, as studies have reported patient outcomes better than the current gold standard V.A.C.® Therapy.
- Traditional V.A.C.® Therapy
- ABTHERA™ Open Abdomen Negative Pressure Therapy, which provides negative-pressure therapy for temporary abdominal closure to help reduce edema and fluid, empowering primary fascial closure.
- PREVENA™ Negative Pressure Incision Management Therapy, which provides NPWT therapy for closed incisions after a surgical procedure.
Furthermore, all four therapies utilize Acelity’s advanced SENSAT.R.A.C.™ Technology with EASYCLEAR PURGE™ which employs advanced software and algorithms in addition to multi-lumen technology that works together to monitor and regulate the set pressure continuously at the wound site, as well as helping reduce blockages. Acelity’s recently launched V.A.C. VERAFLO CLEANSE CHOICE™ dressing for use with V.A.C. VERAFLO™ Therapy helps loosen, solubilize, detach, and remove viscous wound exudate without surgical intervention, effectively preparing the wound for closure.
“Acelity’s software upgrade has also improved the ease-of-use factor for the V.A.C.ULTA™ 4 Therapy System,” said Riley. “Acelity has designed the interface to be similar to a mobile phone, with applications (apps) corresponding to each therapy for easy selection; thus, reducing the number of steps needed for therapy delivery.”
Acelity conducts hands-on training for clinicians, as well as transitioning training for customers moving to the new V.A.C.ULTA™ 4 Therapy System. The company also maintains customer, technical and clinical support teams that are committed to providing detailed support to customers for administrative questions, technological troubleshooting, and can give guidance on use of Acelity’s products.
Acelity also recently launched V.A.C. VERAFLO CLEANSE CHOICE™ Dressing. When used with V.A.C. VERAFLO™ Therapy, Acelity’s negative pressure wound therapy and instillation (NPWTi-d) system, the dressing may provide rapid cleansing of wounds with the goal of augmenting the healing environment. The novel therapeutic dressing facilitates removal of thick wound exudate when surgical debridement is not possible or delayed, and offers prompt adjunctive wound cleansing for complex wounds.
In addition, Acelity has led the way in the next frontier of NPWT with its digital health offerings. iOn RESULTS™ Remote Therapy Monitoring works in conjunction with the V.A.C.ULTA™ Therapy System to monitor the therapy units’ performance in the hospital setting. iOn PROGRESS™ Remote Therapy Monitoring delivers the first continuous monitoring and ready intervention for patients receiving negative pressure wound therapy in the home.
Due to Acelity’s commitment to improve patient outcomes through continuous technological innovation and outstanding customer support, Acelity has earned Frost & Sullivan’s 2017 North American Negative-Pressure Wound Therapy Product Leadership Award.
Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality that is gaining rapid market acceptance. The award recognizes the quality of the solution and the customer value enhancements it enables.
Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
About Acelity
Acelity L.P. Inc. and its subsidiaries are a global advanced wound care company that leverages the strengths of Kinetic Concepts, Inc. and Systagenix Wound Management, Limited. Available in more than 90 countries, the innovative and complementary ACELITY™ product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety, and customer experience. Headquartered in San Antonio, Texas, Acelity employs nearly 5,000 people around the world.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.
Contact:
Estefany Ariza
P: 210.477.8469
F: 210.348.1003
